Skip to Main Content

A version of this article first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

WASHINGTON — Two top Food and Drug Administration officials, suddenly at the center of the White House’s effort to speed approval for Covid-19 vaccines, will recuse themselves from the agency’s considerations about whether to approve those products, according to an email obtained by STAT.


The move is designed to lessen conflict-of-interest concerns, since the FDA’s mission is to skeptically review safety and efficacy evidence for drugs, not push for their approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • So Japan approving REMDESIVIR and the EMA’s imminent aprroval of remdesivir would also be regarded as
    questionable requiring careful review of everyone involved for their potential conflict of interest? Should someone from activist group be included for the covid-19 drug or biologics review processbin order to placate them? Ridiculous!

Comments are closed.